PARAMETRIC PORTFOLIO ASSOCIATES LLC - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 108 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
PARAMETRIC PORTFOLIO ASSOCIATES LLC ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q1 2022$707,000
-14.2%
73,983
-0.8%
0.00%
Q4 2021$824,000
+146.0%
74,606
+64.6%
0.00%
Q3 2021$335,000
+8.4%
45,328
+112.8%
0.00%
Q2 2021$309,000
-25.0%
21,300
+5.4%
0.00%
Q1 2021$412,000
+6.5%
20,203
-7.1%
0.00%
Q4 2020$387,000
+7.2%
21,757
-10.9%
0.00%
Q3 2020$361,000
-79.8%
24,421
-71.4%
0.00%
-100.0%
Q2 2020$1,790,000
+35.5%
85,276
+49.2%
0.00%0.0%
Q1 2020$1,321,000
+62.1%
57,168
+81.6%
0.00%0.0%
Q4 2019$815,000
-24.7%
31,476
-43.4%
0.00%0.0%
Q3 2019$1,083,000
+257.4%
55,573
+199.6%
0.00%
Q2 2019$303,000
-36.7%
18,551
-12.2%
0.00%
Q1 2019$479,000
-6.3%
21,121
+5.7%
0.00%
-100.0%
Q4 2018$511,000
+2.0%
19,982
+30.4%
0.00%
Q3 2018$501,000
+68.1%
15,323
+16.6%
0.00%
Q2 2018$298,000
-57.2%
13,139
-54.2%
0.00%
-100.0%
Q1 2018$696,000
+28.4%
28,682
+47.6%
0.00%0.0%
Q4 2017$542,000
+7.1%
19,434
+31.4%
0.00%0.0%
Q3 2017$506,000
-10.8%
14,792
+3.9%
0.00%0.0%
Q2 2017$567,000
+9.2%
14,243
+1.1%
0.00%0.0%
Q1 2017$519,000
+19.3%
14,090
+3.3%
0.00%0.0%
Q4 2016$435,000
-4.6%
13,634
+8.5%
0.00%0.0%
Q3 2016$456,000
+42.5%
12,571
-10.9%
0.00%0.0%
Q2 2016$320,000
+57.6%
14,102
+30.7%
0.00%
Q1 2016$203,000
+9.7%
10,788
-4.6%
0.00%
Q4 2015$185,00011,3120.00%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q4 2020
NameSharesValueWeighting ↓
Madison Avenue Partners, LP 7,012,226$60,515,5108.59%
Irenic Capital Management LP 2,760,948$23,826,9816.76%
Newtyn Management, LLC 1,841,560$15,892,6633.92%
Weiss Asset Management LP 7,457,060$64,354,4283.81%
Park West Asset Management LLC 1,983,251$17,115,4561.57%
Baupost Group 7,419,226$64,0281.23%
Oasis Management Co Ltd. 953,254$8,226,5820.36%
Chescapmanager LLC 287,333$2,479,6840.32%
GSA CAPITAL PARTNERS LLP 325,985$2,8130.24%
Virtus ETF Advisers LLC 29,232$252,2720.15%
View complete list of THERAVANCE BIOPHARMA INC shareholders